Latest news

• Daily Brief: Biosimilar Herceptin can't make Perjeta cost effective and more

  against potential drug shortages," FDA Commissioner Scott Gottlieb said in a statement.

• Pfizer CEO reckons rebates will disappear, and that’s a positive

  The move also has the support of FDA Commissioner Scott Gottlieb. ... The move also has the support of FDA Commissioner Scott Gottlieb (pictured below), who said in May that removing the so-called ‘safe harbour’for drug rebates under the

• Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

  announced. Meanwhile, the FDA commissioner Scott Gottlieb has also this week launched another broadside against the industry, attacking its efforts to slow the arrival of biosimilars to market.

• FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

  FDA’ s Gottlieb lambasts industry’ s biosimilar-blocking tactics. Speech coincides with Biosimilars Action Plan. ... FDA Commissioner Scott Gottlieb has taken a swipe at biologics developers who use unwarranted delaying tactics to block the launch of

• Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan

  FDA Commissioner Scott Gottlieb published proposals to entice industry investment in antibiotic R&D last month, while the EU and WHO are also funding collaborative initiatives.